Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail

Neurocrine Biosciences has nabbed a phase 2 win, with its investigational med in-licensed from Takeda significantly reducing depression severity among adults with major depressive disorder who haven’t benefited from at least one previous antidepressant.